1. Bray GA, York DA. Leptin and clinical medicine: a new piece in the puzzle of obesity. J Clin Endocrinol Metab 1997; 82: 2771—2776.
2. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli R, Tanaka H, Clay Williams S, Richardson JA, Kozlowski GP, Wilson S, Arch JRS, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terret JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. Orexins and orexin receptors: a family of hypothalamic neuropep-tides and G-pro-tein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 573—585.
3. Smith SR. The endocrinology of obesity. Endocr Metab Clin NA 1996; 25: 921—942.
4. Glass AR. Endocrine aspects of obesity. Med Clin NA 1989; 73:139—160.
5. Von Shoultz B, Carlstrom K. On the regulation of sex-hormone-binding globulin. A challenge of old dogma and outlines of an alternative mechanism. J Steroid Biochem 1989; 32: 327—334.
6. Pasquali R, Casimirri F, Plate L, Capelli M. Characterization of obese women with reduced sex hormone-binding globulin concentrations. Horm Metabol Res 1990; 22: 303—306.
7. Preziosi P, Barrett-Connor E, Papoz L, Roger M, Saint-Paul M, Nahoul K, Simon D. Interrelationship between plasma sex hormone-binding globulin and plasma insulin in healthy adult women: the Telecom study. J Clin Endo-crinol Metab 1993; 76: 283—287.
8. Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin in the human hepatoma (HepG2) cell line by insulin and prolactin. J Clin Endo-crinol Metab 1988; 67: 460—464.
9. Nestler JE, Baralascini CO, Matt DW, Steingold KA, Ply-mate SR, Clore JN, Blackard WG. Suppression of serum insulin diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989; 68: 1027—1032.
10. Poretsky L. On the paradox of insulin-induced hyperan-drogenism in insulin-resistant states. Endocr Rev 1991; 12: 3—13.
11. Bjorntorp P. The association between obesity, adipose tissue distribution and diseases. Acta Med Scand 1988; 723 (Suppl): 121—134.
12. Pasquali R, Casimirri F. The impact of obesity on hyperan-drogenism and polycystic ovary in premenopausal women. Clin Endocrinol (Oxf) 1993; 39: 1—16.
13. Samojlik E, Kirschner MA, Silber D, Schneider G, Ertel NH. Elevated production and metabolic clearance rates of andro-gens in morbidly obese women. J Clin Endocrinol Metab 1984; 59: 949—954.
14. Kurtz BR, Givens JR, Koinindir S, Stevens MD, Karas JG, Bittle JB, Judge D, Kitabki AE. Maintenance of normal circulating levels of A4-androstenedione and dehydro-epiandrosterone in simple obesity despite increased metabolic clearance rates: evidence for a servo-control mechanism. J Clin Endocrinol Metab 1987; 64: 1261—1267.
15. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endo-crinol Metab 1990; 70: 473-479.
16. Siiteri PK. Extraglandular estrogen formation and serum binding of estradiol: relationship to cancer. J Endocrinol 1981; 89: 119P-129P.
17. Grenman S, Konnemaa T, Iryale K, Kaiola HL, Grouroos M. Sex steroid, gonadotropin, cortisol, and prolactin in healthy, massively obese women: correlation with abdominal fat cell size and effect of weight loss. J Clin Endocrinol Metab 1986; 63:1257-1261.
18. Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology and metabolic aberrations in premeno-pausal women. J Clin Endocrinol Metab 1983; 57: 304-310.
19. Pasquali R, Casimirri F, Cantobelli S, Morselli-Labate AM, Venturoli S, Paradisi R, Zannarini L. Insulin and androgen relationship with abdominal body fat distribution in women with and without hyperandrogenism. Horm Res 1993; 39: 179-187.
20. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes 1996; 20: 291-302.
21. Lovejoy JC, Bray GA, Bourgeois MO, Macchiavelli R, Rood JC, Greeson C, Partington C. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women—A clinical research center study. J Clin Endocrinol Metab 1996; 81: 2198-2203.
22. Apter D, Butzow T, Laughlin GA, Yen SSC. Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab 1995; 80: 2966-2973.
23. Cresswell JL, Barker DJP, Osmond C, Egger P, Phillips DIW, Fraser RB. Fetal growth, length of gestation, and polycystic ovaries in adult life. Lancet 1997; 350: 1131-1135.
24. Pasquali R, Casimirri F, Venturoli S, Morselli Labata AM, Reho S, Pezzoli, Paradisi R. Body fat distribution has weight-independent effects on clinical, hormonal, and metabolic features of women with polycystic ovary syndrome. Metabolism 1994; 43: 706-713.
25. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. En-docr Rev 1997; 18: 774-800.
26. Poretsky L, Cataldo NA, Rosewaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20: 1-48.
27. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytoch-rome P450c17a activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617-623.
28. Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992; 36: 105-111.
29. Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R, Balestra V, Melchionda N, Barbara L. Clinical and hormonal characteristics of obese amenorrheic hy-perandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173-179.
30. Dunaif A, Scott D, Finegood D, Quantana B, Whitcomb R. The insulin-sensitizing agent, troglitazone, improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299-3306.
31. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340: 1314-1320.
32. Yen SSC. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1980; 12:177-208.
33. Reid RL, Yen SSC. ^-endorphin stimulates the secretion of insulin and glucagon in humans. J Clin Endocrinol Metab 1981; 52: 592-594.
34. Givens JR, Wiedemann E, Andersen RN, Kitabchi AE. endorphin and ^-lipotropin plasma levels in hirsute women: correlation with body weight. J Clin Endocrinol Metab 1980; 50:915-917.
35. Wild RA, Painter PC, Coulson RB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61: 946-951.
36. Ehrmann DA, Rosenfield RL, Barnes, RB, Brigell DF, Sheikh Z. Detection of functional hyperandrogenism in women with androgen excess. N Engl J Med 1992; 327: 157-162.
37. Yakubowicz DJ, Nestler JE. 17a hydroxyprogesterone response to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab 1997; 82: 556-560.
38. Zumoff B, Strain G, Miller LK, Rosner W, Senie R, Seres D, Rosenfield RS. Plasma free and non-sex-hormone-binding-globulin-bound testosterone are decreased in obese men in proportion to their degree of obesity. J Clin Endo-crinol Metab 1990; 71:929-931.
39. Tchernoff A, Despres J-P, Belanger A, Dupont A, Prud'homme D, Moorjani S, Lupien PJ, Labrie F. Reduced testosterone and adrenal C19 steroid levels in obese women. Metabolism 1995; 44: 513-519.
40. Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, and its relation to plasma andro-gens in hypogonadism of obese men. J Clin Endo-crinol Metab 1993; 76:1140-1146.
41. Seidell JC, Bjorntorp P, Sjostrom L, Kvist H, Sannerstet R. Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism 1990; 39: 897-901.
42. Khaw KT, Barret-Connor E. Lower endogenous androgens predict central adiposity in men. Ann Epidemiol 1992; 2: 675-682.
43. Pasquali R, Casimirri F, Cantobelli S, Melchionda N, Mor-selli Labate AM, Fabbri R, Capelli M, Bortoluzzi L. Effect obesity and body fat distribution on sex hormones and insulin in men. Metabolism 1991; 40: 101-104.
44. Leenen R, van der Koy K, Seidell JC, Deurenberg P, Kopperschaar HPF. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J Clin Endocrinol Metab 1994; 78:1515-1520.
45. Tchernoff A, Labrie F, Belanger A, Prud'homme D, Bouchard C, Tremblay A, Nadeau A, Despres JP. Andros-tane-3alpha, 17^-Diol glucuronide as a steroid correlate of visceral obesity in men. J Clin Endocrinol Metab 1997; 82: 1528-1534.
46. Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S,
Chierici R, Flamia R, Biscott M, Vicennati V. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 1995; 80: 654-658.
47. Lopez Blanco F, Fanjiul LF, Ruiz de Galarreta CM. The effect of insulin and lutenizing hormone treatment of serum concentrations of testosterone and dihydrotestosterone and testicular 3^-hydroxysteroid-dehydrogenase activity in intact and hypophysectomized rats. Endocrinology 1989; 109: 1248-1253.
49. Pasquali R, Macor C, Vicennati C, Novo F, De Iasio R, Mesini P, Boschi S, Casimirri F, Vettor R. Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism 1997; 46: 526-529.
50. Pasquali R, Vicennati V, Scopinaro N, Marinari G, Flamia R, Casimirri F, Gagliari L. Achievement of near-normal body weight as the prerequisite to normalize sex hormone-binding globulin concentrations in massively obese men. Int J Obes 1997; 21:1-5.
51. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm
G, Lindstedt G, Bjorntorp P. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes 1992; 16: 991-997.
52. Veldhuis JD, Iranmanesh A, Ho KKY, Waters MJ, Johnson ML, Lizarralde G. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropinism of obesity in man. J Clin Endocrinol Metab 1991; 72: 51-59.
53. Kopelman PG. Neuroendocrine function in obesity. Clin Endocrinol (Oxf) 1988; 28: 675-689.
54. Cordido F, Casanueva FF, Dieguez C. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects. J Clin Endocrinol Metab 1989; 68: 290-293.
55. Dubey AK, Hanukoglu A, Hamsen BC, Kowarski AA. Metabolic clearance rates of synthetic human growth hormone in lean and obese male rhesus monkeys. J Clin Endocrinol Metab 1988; 67: 1064-1067.
56. Williams T, Berelowitz M, Joffe J, Thorner MO, Rivier J, Vale W, Frohman LA. Impaired growth hormone responses to growth-hormone releasing factor in obesity. A pituitary defect reversed with weight reduction. N Engl J Med 1984; 311:1403-1407.
57. Cordido F, Penalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 1993; 76: 819-823.
58. Lee EJ, Nam SY, Kim KR, Lee HC, Cho JH, Nam MS, Song YD, Lim SK, Huh KB. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects. J Clin Endocrinol Metab 1995; 80: 2495-2498.
59. Frystyk J, Vestbo E, Skjaerbaek C, Mogensen CE, 0rskov
H. Free insulin-like growth factors in human obesity. Metabolism 1995; 44 (Suppl) 37-44.
60. Rasmussen MH, Frystyk J, Andersen T, Breum L, Christian sen JS, Hilsted J. The impact of obesity, fat distribution and energy restriction on insulin like growth-factor-1 (IGF-1) IGF-binding protein-3, insulin and growth hormone. Metabolism 1994; 43:315-319.
61. Rasmussen MH, Hvidberg A, Juul A, Main KM, Gotfredsen A, Skakkebs NE, Hilsted J. Massive weight loss restores 24-hour growth hormone release profiles and serum insulinlike growth factor-1 levels in obese subjects (published erratum appears in J Clin Endocrinol Metab 1995; 80: 2446) J Clin Endocrinol Metab 1995: 80:1407-1415.
62. Williams T, Frohman LA. Potential therapeutic implications for growth hormone and growth-hormone releasing hormone in conditions other than growth retardation. Pharmacotherapy 1986; 6: 311-318.
63. Rosembaum M, Gertner JM, Leibel R. Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children. J Clin Endocrinol Metab 1989; 69: 1274-1281.
64. Solomon F, Cenco RC, Herp R, Sonksen PH. The effects of treatment with recombinant human GH on body composition and metabolism in adults with GH deficiency. N Engl J Med 1989; 321: 1797-1803.
65. Rudman D, Feller AG, Nagrai HS, Gergans GA, Lalitha PA, Goldberg AF, Schlenker RA, Cohn L, Rudman IW, Matt-son DE. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323:1-6.
66. Hwu CM, Kwok CF, Lai TY, Shih KC, Lee TS, Hsiao LC, Lee SH, Fang VS, Ho LT. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab 1997; 82: 3285-3292.
67. Skaggs SR, Crist DM. Exogenous human growth hormone reduces body fat in obese women. Horm Res 1991; 35:19-24.
68. McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diab Metab Rev 1988; 4: 17-30.
69. Bjorntorp P. Visceral obesity: a 'Civilization syndrome'. Obes Res 1993; 1: 206-222.
70. Bujalska IJ, Kumar S, Stewart PM. Does central obesity reflect 'Cushing's disease of the omentum'? Lancet 1997; 349: 1210-1213.
71. Bujalska IJ, Kumar S, Hewison M, Stewart PM. Differentiation of adipose stromal cells: the roles of glucorticoids and 11^-hydroxysteroid dehydrogenase. Endocrinology 1999; 140:3188-3196.
72. Andrew R, Phillips DIW, Walker BR. Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998; 83: 1806-1809.
73. Stewart PM, Boulton A, Kumar S, Clark PMS, Shachleton CHL. Cortisol metabolism in human obesity: impaired cor-tisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999; 84: 1022-1027.
74. Chalew S, Nagel H, Shore S. The hypothalamic-pituitary-adrenal axis in obesity Obes Res 1995; 3: 371-382.
75. Marin P, Darin N, Anemiya T, Anderson B, Jern S, Bjorntorp P. Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992; 41: 882-886.
76. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi F, Flamia R, Morselli-Labate AM, Barbara L. The hy-pothalamic-pituitary-adrenal axis in obese women with dif ferent patterns of body fat distribution. J Clin Endo-crinol Metab 1993; 77: 341-346.
77. Duclos M, Corcuff J-B, Etcheverry N, Rushedi M, Tabarin A, Roger P. Abdominal obesity increases overnight cortisol excretion. J Endocrinol Invest 1999; 22: 465-471.
78. Pasquali R, Biscotti M, Spinucci G, Vicennati V, Genazzani AD, Sgarbi L, Casimirri F. Pulsatile rhythm of ACTH and cortisol in premenopausal women: effect of obesity and body fat distribution. Clin Endocrinol (Oxf) 1998; 48: 603-612.
79. Licinio J, Mantzoros C, Negrao AB, Cizza G, Wong ML, Bongiorno PB, Chrousos GP, Karp B, Allen C, Flier JS, Gold PW. Human leptin levels are pulsatile and inversely related to pituitary-adrenal function. Nat Med 1997; 3: 575-579.
80. Quigley ME, Yen SSC. A mid-day surge in cortisol levels. J Clin Endocrinol Metab 1979; 49: 945-947.
81. Korbonits M, Trainer PJ, Nelson ML, Howse I, Kopelman PG, Besser GM, Grossman AB, Svec F. Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Clin Endocrinol (Oxf) 1996; 45: 699-706.
82. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynic abnormalities. J Clin Endocrinol Metab 1998; 83:1853-1859.
83. Weaver JU, Kopelman PG, McLoughlin L, Forsling MI, Grossman A. Hyperactivity of the hypothalamic-pituitary-adrenal axis in obesity: a study of ACTH, AVP, ^-lipotropin and cortisol responses to insulin-induced hypoglycemia. Clin Endocrinol (Oxf) 1993; 39: 345-350.
84. Pasquali R, Anconetani B, Chattat, Biscotti M, Spinucci G, Casimirri F, Vicennati V, Carcello A, Morselli-Labate AM. Hypothalamic-pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of cortico-tropin-releasing factor/arginine-vasopressin test and of stress. Metabolism 1996; 45: 351-356.
85. Moyer AE, Rodin J, Grilo CM, Cummings N, Larson LM, Rebufie-Scrive M. Stress-induced Cortisol response and fat distribution in women. Obes Res 1994; 2: 255—262.
86. Boushaki FZ, Rasio E, Serri O. Hypothalamic-pituitary-adrenal axis in abdominal obesity: effects of dexfenfluramine. Clin Endocrinol (Oxf) 1997; 46: 461—466.
87. Pasquali R, Gagliardi L, Vicennati V, Gambineri A, Colitta D, Ceroni L, Casimirri F. ACTH and cortisol responses to combined corticotropin releasing hormone-arginine vasop-ressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. Int J Obes 1999; 23: 419—424.
88. Ljung T, Anderson B, Bengtsson BA, Bjorntorp P, Marin P. Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose—response study. Obes Res 1997; 4: 277—282.
89. Shively C, Clarkson T. Regional obesity and coronary atherosclerosis in females: a non-human primate model. Acta Med Scand 1979; 723 (Suppl): 71—78.
90. Lapidus L, Bengtson C, Hallstrom T, Bjorntorp P. Obesity, adipose tissue distribution and health in women from a population study in Gotenborg, Sweden. Appetite 1989; 12: 25—35.
91. Rosmond R, Bjorntorp P. Endocrine and metabolic aberrations in men with abdominal obesity in relation to anxio-depressive infirmity. Metabolism 1998; 47:1187—1193.
92. Rosmond R, Lapidus L, Bjorntorp P. The influence of occupational and social factors on obesity and body fat distribution in middle-aged men. Int J Obes 1996; 20: 599—607.
93. Rosmond R, Lapidus L, Marin P, Bjorntorp P. Mental distress, obesity and body fat distribution in middle-aged men. Obes Res 1996; 4: 245—252.
94. Pasquali R, Vicennati V, Calzoni F, Gnudi U, Gambineri A, Ceroni L, Coltelli P, Menozzi R, Sinisi R, Del Rio G. <x2-adrenoreceptor regulation of the hypothalamic-pituitary-adrenocortical axis in obesity. Clin Endocrinol 2000; 52: 413—421.
International Textbook of Obesity. Edited by Per Bjorntorp.
Copyright © 2001 John Wiley & Sons Ltd Print ISBNs: 0-471-988707 (Hardback); 0-470-846739 (Electronic)
Was this article helpful?